
Are You Staying Informed With New Diabetes Treatments?
Poll finds less than half of health care professionals aware of newest drug up for FDA approval.
By Steve Freed, R.Ph., Diabetes Educator, Publisher
In the past two years, more than 30 medications have come to the market, and more than 475 additional diabetes drugs are in the works to get approved.
To test the knowledge of endocrinologists, 149 endocrinologists responded to a survey about a new drug that the FDA is looking to approve shortly. The drug, ertugliflozin, met the primary outcomes in two year-long phase 3 trials, VERTIS SU and VERTIS SITA2 and only 45% of the physicians said they had heard of the drug. Of those, 20% knew it only by name and only 5% were “very familiar” with it.
Ertugliflozin is an investigational oral sodium-glucose co-transporter 2 (SGLT-2) inhibitor aimed at improving glycemic control in adults. It is expected to be approved before the end of the year, which would make it the fourth drug in its class to market.
Respondents were asked, after reading the clinical trial data provided about the drug and assuming ertugliflozin is approved and performs as described, how long they thought it would take for them to start prescribing. Only 7% answered that they would start prescribing within the first week, another 18% said they would prescribe it in the first month, and nearly half (46%) said they would prescribe it within 2 to 6 months. Just more than 1 in 5 (21%) said they would likely wait at least 9 months before prescribing.
Among the 113 endocrinologists who anticipated prescribing ertugliflozin, the main reason given was efficacy (58% answer
Continue
reading